CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biopharmaceutical company, announced today that Dr. Spyridon "Spyros" Papapetropoulos has joined as Executive Vice President, Research and Development and Chief Medical Officer. Dr. Papapetropoulos will lead Cavion’s research and development organization to advance therapies based on the company’s T-type calcium channel (Cav3) platform.
“Spyros joins the Cavion team at an exciting time. He is an experienced leader with a passion for conducting innovative trials that deliver new treatment options to patients with neurological diseases with limited treatment options,” said Cavion CEO and President Andrew Krouse. He added, “Spyros will help extend Cavion’s presence in the Boston/Cambridge area.”
Dr. Papapetropoulos noted, “Cavion’s selective Cav3 modulating platform, which includes best-in-class clinical stage compounds, is expected to restore rhythmic neuronal firing in brain regions associated with a variety of chronic neurological diseases.” He added, “I look forward to working closely with Cavion’s team to apply innovative but empathetic approaches to achieving clinical breakthroughs. Our end goal is to bring safe, effective and accessible treatments to people with chronic neurological diseases, quickly and efficiently.”
For full article, visit Business Wire